For the past decade, many medical journals have begun requiring contributors to disclose their conflicts of interest, but a new study finds that many journal editors — who are also doctors — themselves receive hefty payments from industry and most of their journals do a poor job of disclosing relevant policies.

To wit, the study found that, in 2014, half of 713 journal editors, whose payments were reported to a U.S. government database, had received something of value from drug or device makers, and nearly 10 percent had received research funding. While the median general payment was only $11, the range was large — from $0 to more than $2,900. And two editors received more than $1 million in payments.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy